Tempest Therapeutics, Inc. (TPST)
NasdaqCM
Price as at 1 Oct 2026, 02:51 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Tempest Therapeutics, Inc. trades at $0.83. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its TPST data?
Fundamentals for TPST come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 02:51 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for TPST, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.